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SUMMARY
Introduction: In HIV-infected patients, colonization of the oral cavity by potential pathogenic yeast may lead to development of 
systemic fungemia. We evaluated the prevalence of yeast in the oral cavity of Brazilian HIV-positive patients and verified whether 
or not the species characterized were enzymatically active. Furthermore, the species identified were tested for their susceptibility to 
antifungal treatment. Methods: Patient saliva and oropharyngeal candidiasis samples were collected from 60 seropositive HIV patients 
and identified by the API20C system. Enzymatic activity was evaluated by the production of proteinase and phospholipase. Susceptibility 
to antifungal treatments were determined using the broth microdilution method. Results: the most commonly isolated species were 
C. albicans (51.56%) followed by non-albicans Candida species (43.73%), Trichosporon mucoides (3.12%) and Kodamaea ohmeri 
(1.56%). Oral colonization by association of different species was observed in 42% of the patients. Enzymatic activity was verified 
in most of species isolated, except for C. glabrata, C. lusitaniae and C. guilliermondii. Resistance to Fluconazole and Amphotericin 
B was observed in isolates of C. albicans, C. glabrata, C. parapsilosis, C. krusei, and K. ohmeri. Conclusion: HIV-positive patients 
are orally colonized by single or multiple species of yeast that are occasionally resistant to Fluconazole or Amphotericin B. 
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INTRODUCTION
Candida spp. colonizes skin and mucosal surfaces of the genital and 
intestinal tracts as well the oral cavity under normal healthy conditions29. 
However, under immunocompromising conditions, such as when a patient 
is infected with human immunodeficiency virus (HIV), the colonization 
may grow out of control and rapidly turn into a symptomatic infection39. 
Protection against yeast conversion from a passive colonizer to an 
invasive pathogen is provided by both systemic and local immunity. 
T-helper type 1 (Th1) immunity provided by CD4+ T-lymphocytes is a 
critical component of that protection, however secondary defense is also 
provided by CD8+ T-lymphocytes and epithelial cells through a variety 
of mechanisms previously described39.
In fact, oropharyngeal candidiasis (OPC) is the most frequent 
opportunistic infection encountered in HIV-infected individuals. The 
disease occurs in up to 90% of patients during the course of HIV 
infection3. The occurrence of OPC is associated with CD4+ T-lymphocyte 
levels below 200 cells/mm3, high HIV viral load and disease progression. 
The prolonged course of HIV infection predisposes these patients to 
recurrent episodes of OPC that can increase in frequency and severity 
during the course of HIV disease progression3,13.
Several virulence factors contribute to the pathogenicity of Candida 
spp. including the ability to change cell morphology, a capacity to adhere 
to epithelial cells as well as the potential to secrete extracellular enzymes 
such as phospholipases and aspartyl proteinases6,22,35.
 Phospholipases participate in the breakdown of phospholipids in 
host cell membranes while secretory aspartyl proteinases degrade several 
physiologically important substrates such as albumin, immunoglobulin 
and skin proteins, contributing to tissue penetration by Candida spp. and 
subsequent invasion of the host during the process of infection11,12,14,21. 
C. albicans is the predominant species associated with mucosal and 
systemic fungal infections from yeast18,26. Nevertheless, the epidemiology 
of yeast infection is rapidly evolving and non-albicans Candida species 
as well as rare yeasts have emerged as major opportunistic pathogens. 
The most common non-albicans Candida species are C. glabrata, C. 
parapsilosis, C. tropicalis and C. krusei which have been frequently 
isolated from oral and systemic candidiasis. Other yeasts that are less 
common than Candida have been associated with life-threatening 
infections in immunocompromised hosts, such as Trichosporon, 
Rhodotorula, Non-neoformans Cryptococcus species, Geotrichum, 
Hansenula anomala13 and Kodamaea ohmeri17,37.
Although the importance of these emerging opportunist yeasts 
is recognized, little is known about their epidemiological traits, 
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virulence factors and susceptibility to antifungal treatment. In the 
present study, we evaluated the prevalence of pathogenic yeast from 
saliva and oropharyngeal candidiasis of HIV-positive patients and 
correlated these data with CD4+ lymphocyte counts. Additionally, 
we tested the phospholipase and proteinase activity of Candida spp. 
and non-Candida species identified, as well as their susceptibilities to 
antifungal treatment. 
MATERIALS AND METHODS
Subjects: A total of 60 seropositive HIV patients (diagnosed by 
ELISA and Western-blot) under anti-retroviral therapy at the Emílio Ribas 
Institute of Infectious Diseases (São Paulo, Brasil) were included in this 
study. All of the patients agreed to participate in the study by signing 
an informed consent form approved by the Research Ethics Committee 
of the São José dos Campos School of Dentistry/UNESP (protocol 
051/2009-PH/CEP) and Ethics Committee of the Emílio Ribas Institute 
of Infectious Diseases (protocol 274/2009).
Participants were recruited from September 2009 to May 2010 
and recent data on CD4+ T-lymphocyte counts were obtained from 
their medical records. Of 60 patients studied, seven patients (11.66%) 
presented symptoms of oropharyngeal candidiasis and 53 did not have 
such lesions in the oral cavity (88.33%). 
Sample collection: In the patients with oropharyngeal candidiasis, 
samples were obtained by firmly swabbing the lesion site with a sterile 
cotton wool swab. The swabs were cultured on Sabouraud dextrose agar 
(Difco, Detroit, USA) supplemented with chloramphenicol (100 µg/mL) 
and chromogenic HiCrome Candida agar (Himedia, Munbai, India). 
HiCrome Candida agar is a differential culture medium that is claimed 
to facilitate the isolation and identification of C. albicans, C. tropicalis, 
C. krusei and C. glabrata. The samples were then incubated aerobically 
at 37 °C for 48 hours.
In patients without oral candidiasis, samples from saliva were 
collected by oral rinses in buffered phosphate saline (PBS, 0.1 M, pH 7.2) 
for one min. The samples were centrifuged for 10 min at 8,000g and the 
supernatant was discarded. Next, 2.5 mL of PBS was added to the pellet. 
Ten-fold serial dilutions were carried out and aliquots of 100 µL were 
seeded on Sabouraud dextrose agar (Difco, Detroit, USA) and HiCrome 
Candida agar (Himedia, Munbai, India). After 48 hours of incubation at 
37 °C the colony forming units (CFU/mL) were counted. The positive 
and negative yeast cultures from saliva were compared for variables of 
age and CD4+ lymphocyte counts using a Student’s t test by the Minitab 
Program. A probability (p) of < 0.05 was considered significant.
Yeast isolates were selected for species level identification by colony 
morphology on Sabouraud agar and colony color on HiCrome Candida 
agar. In clinical samples with different colonies, one isolate of each 
colony was obtained for species identification. 
Yeast isolates identification: Identification of the species of the 
isolates was performed by standard methods (germ-tube formation, 
cornmeal agar chlamydospore and hyphae production) and by the 
API20C system (BioMérieux, Paris, France) for sugar assimilation. 
Isolates phenotypically identified as C. albicans or C. dubliniensis were 
confirmed using a multiplex polymerase chain reaction (PCR) procedure, 
as previously described2,32. For PCR, two pairs of primers were used: two 
universal primers, Uni-f: 50-GCATATCAATAAGCGGAGGAAAA-30 
and Uni-r: 50-GGTCCGTGTTTCAAGACG-30; and two C. dubliniensis-
specific ones, DUBF Act-f: 50GTATTTGTCGTTCCCCTTTC-30 e 
DUBR Act-r: 50-GTGTTGTGTGCACTAACGTC-30.
Phospholipase and proteinase activity: Phospholipase production 
in the yeast isolates was assayed using the egg-yolk agar plate method 
of PRICE et al.30. Sabouraud dextrose agar plates containing 57.3 g 
NaCl, 0.55 g CaCl2 and 8% sterile egg-yolk emulsion were used. Test 
strains were spot inoculated and plates were incubated at 37 °C for up 
to five days. Each isolate was tested in duplicate. The diameter of each 
colony and the total diameter of the colony and precipitation zone (Pz) 
were measured. Furthermore, phospholipase activity was scored. The Pz 
value, representing the ratio of colony diameter alone to the diameter 
of the colony plus precipitation zone, was determined. The results were 
classified as negative (Pz = 1 cm), positive (0.64 cm ≥ Pz < 1 cm) and 
strongly positive (Pz < 0.64 cm). By this classification system, a high 
Pz value indicates low enzymatic activity.
The isolates were tested for proteinase secretion in bovine serum 
albumin (BSA) agar that contained yeast carbon base (1.17%); yeast 
extract (0.01%) and BSA (0.2%), according RUCHEL et al.33. The 
medium was adjusted to pH 5.0, sterilized by filtration and added to 
autoclaved 2% agar. Test strains were spot inoculated and plates were 
incubated at 37 °C for up to five days. Each isolate was tested in duplicate. 
Post-incubation, plates were stained with 0.5% amido black and the zone 
of clearance around the colony was recorded. Scoring was carried out 
by determination of the proteinase zone (Pz) value, by the same method 
used to determine phospholipase activity.
Antifungal susceptibility testing: Susceptibility patterns of the yeast 
isolates to nystatin, fluconazole and amphotericin B (Sigma-Aldrich, 
Steinheim, Germany) were determined by a broth-microdilution assay, in 
duplicate, according to document M27-A2 of the Clinical and Laboratory 
Standards Institute (CLSI)4.
Fluconazole was dissolved in sterile distilled water while nystatin 
and amphotericin B were dissolved in dimethyl sulfoxide (Sigma-
Aldrich, Steinheim, Germany) to make stock solutions. RPMI 1640 
medium with L-glutamine without sodium bicarbonate and buffered with 
morpholinepropanesulfonic acid (MOPS) at 0.165 M (Sigma-Aldrich, 
Steinheim, Germany) was used as a test medium. The range of fluconazole 
concentrations tested was from 0.125 to 64 µg/mL, while amphotericin B 
and nystatin were tested within the range of 0.031 to 16 µg/mL.
The inoculum of Candida strains was grown in Sabouraud dextrose 
agar for 48 h at 35 °C. This solution was prepared in 5 mL sterile 
saline (0.85%) and the cellular density at 0.284 was adjusted on a 
spectrophotometer (B582, Micronal, São Paulo, Brazil) at wavelength 
= 530 nm, resulting in a standard solution with 1x106 cells/mL. The 
standard solution was diluted in RPMI 1640 in order to obtain a final 
concentration of 1x103 to 5x103 cells/mL. 
The microplates were incubated at 37 °C for 48 hours. The Minimal 
Inhibitory Concentration (MIC) for fluconazole was defined by the lowest 
concentration of the drug resulting in an 80% reduction in turbidity, in 
comparison with drug-free growth control, and for amphotericin B and 
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nystatin the MIC values were defined by the lowest concentration of drug 
resulting in complete inhibition of visible growth. Results are expressed 
as a range of minimum and maximum MIC values as well as by the values 
of MIC
50
 (the MIC at which 50% of the isolates are inhibited) and MIC
90 
(the MIC at which 90% of the isolates are inhibited). 
The following resistance breakpoints were used according to CLSI 
guidelines for all yeasts isolated. For fluconazole, MICs of ≤ 8 µg/mL 
were considered to be susceptible, 16-32 µg/mL to be susceptible but 
dose-dependent and ≥ 64 µg/mL to be resistant. There were no CLSI 
breakpoints defined for nystatin and amphotericin B. For susceptibility 
to amphotericin B, the breakpoint established by YANG et al.41 was 
adopted as follows: isolates with MIC ≥ 2 µg/mL were considered to be 
resistant, and those with MIC ≤ 1 µg/mL were susceptible. 
RESULTS
Patient data: Of the 60 patients examined, 39 (65%) were men and 
21 (35%) were women. The mean age was 43 years, and the total range 
of ages was from 29 to 63 years. Their CD4+ lymphocyte counts ranged 
from 97 to 2021 cells/mm3 with a mean count of 739 cells/mm3.
Of 53 patients without clinical lesions from candidiasis in the oral 
cavity, 33 (62%) presented positive cultures for yeast in the saliva and 
20 (38%) showed negative cultures. The number of colony-forming 
units ranged from 0 to 72,000 CFU/mL with a mean value of 5,230 
CFU/mL and a median value of 300 CFU/mL. The patient age and 
CD4+ lymphocyte counts were compared between groups with positive 
and negative cultures. This analysis indicated no significant statistical 
difference between the groups (Table 1).
Prevalence and distribution of isolates: One isolate of each species 
from the same patient was analyzed with a total of 64 isolates obtained. 
Fifty-one isolates were obtained from the saliva of 33 patients without oral 
candidiasis and 13 from seven patients with oropharyngeal candidiasis. 
C. albicans was the most frequently isolated species followed by C. 
glabrata. The distribution of all isolated species is shown in Table 2.
Of the 40 patients with positive yeast cultures (33 patients without 
oral candidiasis and seven patients with oropharyngeal candidiasis), 23 
(58%) presented oral colonization or infection by single yeast species 
(19 from saliva and four from OPC) and 17 (42%) showed colonization 
by association of multiple species (Table 3).
Phospholipase and proteinase activity of isolates: Phospholipase 
activity was observed in all isolates of C. albicans, C. dubliniensis, 
C. tropicalis, C. krusei, C. novergensis, T. mucoides and K. ohmeri. 
Proteinase activity was found in all isolates of C. albicans, C. 
parapsilosis and C. dubliniensis. However, C. glabrata, C. lusitaniae 
and C. guilliermondii were negative for phospholipase and proteinase 
activity (Table 4).
Antifungal susceptibility of yeast isolates: The range of susceptibilities 
to Fluconazole and Amphotericin B is summarized in Table 5. Most isolates 
were susceptible to Fluconazole (81.25%) and Amphotericin B (93.75%). 
The resistance to Fluconazole was observed in nine (27%) isolates of C. 
albicans, one isolate of C. glabrata, one isolate of C. krusei and one isolate 
Table 1 
Patient age and CD4+ T-lymphocyte counts indicating both positive and 







Age 44.4 ± 8.1 41.4 ± 7.0 0.158
CD4+ lymphocytes 762.6 ± 452.1 700.9 ± 379.8 0.597
Student t test (p < 0.05) 
Table 2 
Frequency of yeast species isolated from saliva and oropharyngeal candidiasis (OPC) in HIV-positive patients 
Yeast species
Frequency (%)
All isolates (n = 64) Saliva (n = 51) OPC (n = 13)
n % n % n %
C. albicans 33 51.56 25 49.00 8 61.53
C. glabrata 10 15.62 8 15.68 2 15.38
C. parapsilosis 5 7.81 4 7.84 1 7.69
C. dubliniensis 4 6.25 4 7.84 - -
C. tropicalis 4 6.25 3 5.88 1 7.69
C. krusei 2 3.12 1 1.96 1 7.69
C. lusitaniae 1 1.56 1 1.96 - -
C. guilliermondii 1 1.56 1 1.96 - -
C. norvegensis 1 1.56 1 1.96 - -
T. mucoides 2 3.12 2 3.92 - -
K. ohmeri 1 1.56 1 1.96 - -
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of K. ohmeri. The resistance to Amphotericin B was verified in three isolates 
of C. parapsilosis and one isolate of C. krusei. The MIC to Nystatin was 
4 µg/mL for all species studied, except for C. parapsilosis and C. krusei 
in which MICs ranged from 4 to 8 µg/mL.
DISCUSSION
Although the incidence of oropharyngeal candidiasis has declined 
for HIV-infected patients with access to antiretroviral therapy (ART), it 
remains a significant problem for those in locations with limited resources 
or those with a poor immunologic response, despite the ART treatment38. 
In this study, we evaluated 60 HIV-positive patients under anti-retroviral 
therapy. Seven patients had oropharyngeal candidiasis and 53 did not 
have candidiasis lesions. 
Among the 53 patients without candidiasis, 62% were positive 
for oral carriage of yeast. These data are similar to epidemiological 
studies performed in Thailand10, India9 and Argentina20 that found 
respectively 61, 68 and 72% of HIV-positive patients to be subject to 
oral colonization by yeast. However, more instances of yeast carriage 
among HIV-positive patients were observed in Turkey, with 82% of 
patients positive for yeast in the oral cavity7. Some studies showed that 
the prevalence of yeasts in the oral cavity of HIV-negative individuals 
ranged from 46 to 56%2,32.
The number of colony-forming units in the saliva of HIV-positive 
patients without clinical lesions showed a median value of 300 CFU/
mL. BACK-BRITO et al.2 detected more cases of Candida spp. in the 
oral cavity of HIV-positive patients (median value of 860 CFU/mL and 
interquartile range of 3250 CFU/mL) in relation to the control group 
(median value of 0 CFU/mL and interquartile range of 480 CFU/mL). 
The absolute CD4+ T-lymphocyte count has traditionally been cited 
as the greatest risk factor for switching the status of asymptomatic 
yeast colonization to the development of oropharyngeal candidiasis, 
and current guidelines suggest an increased risk once the CD4+ 
T-lymphocyte count falls to < 200 cells/µL39. In this study, we found 
no difference in the CD4+ T-lymphocyte counts between patients 
positive or negative for oral carriage of yeast. Other studies have also 
found no correlation between CD4+ T-lymphocyte counts and yeast 
colonization2,7,19,20. On the other hand, BACK-BRITO et al.2 and YANG 
et al.40 observed significantly lower yeast counts in patients with a 
lower viral load (< 400 copies/mL), suggesting that viral load might 
be a higher risk factor for the occurrence of candidiasis as compared 
to the CD4+ T-lymphocyte count.
Table 3
Number of HIV-positive patients colonized by multiple yeast-species from 
saliva and oropharyngeal candidiasis (OPC) 






C. albicans + C. glabrata 4 1
C. albicans + C. dubliniensis 1 -
C. albicans + C. tropicalis 1 1
C. albicans + T. mucoides 1 -
C. albicans + K. ohmeri 1 -
C. parapsilosis + C. glabrata 1 -
C. parapsilosis + C. dubliniensis 1 -
C. albicans + C. dubliniensis + 
C. parapsilosis
1 -
C. albicans + C. novergensis + C. krusei 1 -
C. dublinienis + C. tropicalis + C. glabrata 1 -
C. glabrata + C. parapsilosis + T. mucoides 1 -




Number of yeast isolates according to phospholipase and proteinase activity as determined by PRICE et al. (1982)
Species (No. of isolates)
Phospholipase activity Proteinase activity 
Negative Positive Strongly positive Negative Positive Strongly positive
C. albicans (33) - 15 18 - 16 17
C. glabrata (10) 10 - - 10 - -
C. parapsilosis (5) 5 - - - - 5
C. dubliniensis (4) - 4 - - 4 -
C. tropicalis (4) - 3 2 4 - -
C. krusei (2) - 2 - 2 - -
C. lusitaniae (1) 1 - - 1 - -
C. guilliermondii (1) 1 - - 1 - -
C. norvegensis (1) - 1 - 1 - -
T. mucoides (2) - - 2 2 - -
K. ohmeri (1) - - 1 1 - -
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In the present study, C. albicans was the most common species 
isolated in the saliva of patients both without clinical lesions (49%) and 
oropharyngeal candidiasis (61%). These results support previous studies 
performed in the oral cavity of HIV-positive patients3,13,27,40. Even though 
C. albicans was the most common species recovered, the non-albicans 
Candida species have become more recognized as a major source of 
infection. This hypothesis was supported by this study in which 49% of 
isolates were identified as non-albicans species.
Among non-albicans isolates, C. glabrata was the most frequently 
isolated species from the saliva of patients without clinical lesions and 
from oropharyngeal candidiasis. According to REDDING et al.31, C. 
glabrata has emerged as a notable pathogenic agent in oral mucosa, either 
as a co-infecting agent with C. albicans or as the sole detectable species 
from oral lesions. In addition, C. glabrata-associated oropharyngeal 
candidiasis infections in HIV-positive patients tend to be more severe and 
more difficult to treat than infections due solely to C. albicans. 
Besides C. glabrata, other common non-albicans Candida species 
were isolated from the oral cavity including C. parapsilosis, C. tropicalis, 
C. krusei, C. lusitaniae, C. guilliermondii, and C. dubliniensis. C. 
dubliniensis was first isolated from oropharyngeal lesions in HIV-positive 
patients in Dublin. It is phenotypically very similar to C. albicans, 
producing both germ tubes and chlamydospores. Since the original 
description in 1995, it has been recovered from 25% of HIV-positive Irish 
patients, with subsequent reports suggesting a worldwide distribution2. In 
this study, C. dubliniensis was identified in 6.25% of isolates. Previous 
findings indicated that the rate of C. dubliniensis oral isolates recovered 
from HIV-postive patients was 0.3% in Tanzania13, 17% in United States 
of America39, and 20% in Argentina20. 
In this study, rare yeast species including C. norvegensis, Kodamaea 
ohmeri and Trichosporon mucoides were also identified by API20C 
system. C. norvegensis was first isolated in Norway 70 years ago and 
appears to be a rare cause of human disease15. SANDVEN et al.34 
identified a total of four invasive infections occurring between 1990 
and 1996 and all isolates of C. norvegensis were fluconazole resistant, 
potentially indicating an inherent characteristic of the species. There 
are only two studies that report isolation of C. norvegensis from the oral 
cavity. Both studies were performed in Brazil with children23 and adults24 
seropositive for HIV.
Kodamaeae (Pichia) ohmeri, a teleomorph of C. guilliermondii var. 
membranaefaciens, is an environmental strain commonly used in the food 
industry. However, it is also an emerging fungal pathogen, particularly 
in immunocompromised patients17. In 2010, SHANG et al. conducted 
a search of English medical literature from 1970 to 2008 and found 
20 reported cases of K. ohmeri infection37. The isolation of K. ohmeri 
from the oral cavity was reported in only one study in which K. ohmeri 
was recovered from oropharyngeal candidiasis in Indian HIV-infected 
patients25. This species has been identified by the API 20C system and 
confirmed by ascospore formation or molecular identification, however 
in this study the identification of K. ohmeri was not confirmed by these 
analyses. 
Trichosporon mucoides were isolated from the oral cavity of two 
patients in this study. This is the first study to describe the isolation of 
this species from the oral cavity. Trichosporon spp. predominantly cause 
superficial skin infections and scalp or pubic white piedra, but they 
can also cause invasive disease in immunocompromised individuals. 
Trichosporonosis, the deep-seated infection caused by this fungus, is an 
often fatal disease with a mortality rate of 80%16,28,36.
 The transformation from harmless commensal yeast to virulent 
pathogen under the conditions of a dysfunctional host-defense system is 
attributable to an extensive repertoire of selectively expressed virulence 
determinants. Phospholipases and proteinases are considered to play 
an important role in Candida overgrowth, as these factors facilitate 
adherence, tissue penetration and subsequent invasion of the host10. 
Phospholipase and proteinase production was found in 100% of C. 
albicans isolates during this study. However, MANE et al.21 verified 
production of phospholipase and proteinase in only 59% and 89.7%, 
Table 5 
Antifungal susceptibilities of yeast isolates as determined by the CLSI microdilution reference broth method 
Species (No. of isolates)









C. albicans (33) 0.125 - >64 0.125 >64 0.125 - 0.5 0.25 0.25
C. glabrata (10) 1 - >64 4 8 0.25 - 0.5 0.5 0.5
C. parapsilosis (5) 0.5 - 64 1 2 0.5 - 2 0.5 2
C. dubliniensis (4) 0.5 - 16 0.5 1 0.125 - 0.25 0.25 0.25
C. tropicalis (4) 0.125 - 2 1 1 0.25 0.25 0.25
C. krusei (2) 32 - 64 32 64 0.5 - 2 0.5 2
C. lusitaniae (1) 0.125 0.125 0.125 0.25 0.25 0.25
C. guilliermondii (1) 2 2 2 0.25 0.25 0.25
C. norvegensis (1) 32 32 32 0.5 0.5 0.5
T. mucoides (2) 2 - 4 2 4 0.25 - 0.5 0.25 0.5
K. ohmeri (1) >64 >64 >64 0.25 0.25 0.25
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respectively, of C. albicans isolates obtained from HIV-positive patients 
with oral candidiasis. 
Among the isolates of non-albicans species identified in this study, 
39% showed phospholipase activity and 21% exhibited proteinase activity. 
Previous studies also reported that proteinases and phospholipases are 
produced at high rates in C. albicans, whilst non-albicans Candida species 
usually present low rates of these enzymes5,8. No isolates of C. glabrata, 
C. lusitaniae or C. guilliermondii exhibited enzymatic activity. Although 
C. glabrata presents a higher mortality rate compared with infection by 
other non-albicans Candida, this species presents a lack of enzymatic 
activity and low virulence in animal models of infection31. According 
to KRCMERY & BARNES15, invasive C. glabrata infection occurs 
predominantly in the illest of patients, such as in the terminal stages 
of malignant disease. This phenomenon explains the somewhat higher 
overall mortality rate observed for C. glabrata in comparison with other 
non-albicans Candida species. 
The present study is the first to describe phospholipase enzymatic 
activity by K. ohmeri and T. mucoides. Of note, these species were unable 
to produce proteinase. However, because these species were isolated from 
the oral cavity, it is necessary to design studies to evaluate their virulence 
in animal models of oral candidiasis. 
Among the patients analyzed in this study, 42% had oral colonization 
or infections by association of Candida species, including two, three or 
four different species in the same patient. LUQUE et al.20 also observed 
that 59% of Argentinian HIV-positive patients carried two or three 
different species of yeast in their oral cavity. C. albicans and C. glabrata 
were the most frequently identified combination of yeast infections in 
our study. This combination was also reported in mixed candidemia by 
MICELI et al.26.
The emergence of yeasts other than C. albicans and of mixed 
infections suggests that the epidemiology of Candida infections is 
changing. Consequently these infections may require higher doses 
of antifungal treatments to resolve. The presence of more than one 
species of Candida in the oral mucosa may predispose patients to 
recurrent candidiasis, mainly caused by species resistant to antifungal 
treatments27,38. 
In this study, some isolates of C. albicans (27%), C. glabrata and K. 
ohmeri were resistant to Fluconazole and isolates of C. parapsilosis and 
C. krusei were resistant to Amphotericin B. Meanwhile, C. parapsilosis 
and C. krusei showed the highest MICs for Nystatin (4 to 8 µg/mL). 
Among clinical oral yeasts from 292 HIV-infected patients in Tanzania 
analyzed by HAMZA et al.13 5% showed resistance to Fluconazole, 
including isolates of C. glabrata, C. tropicalis and C. krusei, and all 
isolates were susceptible to Amphotericin B. The MICs to Nystatin 
ranged from 2 to 8 µg/mL for non-albicans Candida species and from 
2 to 16 µg/mL for C. albicans. BACK-BRITO et al.1 demonstrated that 
Amphothericin B, Fluconazole, Flucytosine, Nystatin and Ketoconazole 
showed good activity for most Candida isolates from the oral cavity of 
HIV-positive patients. However, variability in MIC values among isolates 
was observed, confirming the importance of susceptibility tests as a guide 
to the treatment of oral candidiasis. 
We conclude that oral colonization and infection by yeasts in 
Brazilian HIV-positive patients is composed of different species, 
including C. albicans, non-albicans Candida species and non-Candida 
species. Furthermore, these yeast species frequently form associations 
of two or more species and are resistant to Fluconazole or Amphotericin 
B treatment.
RESUMO
Colonização oral por leveduras em pacientes HIV-positivos no 
Brasil
Introdução: Em pacientes infectados pelo HIV, a colonização da 
cavidade bucal por leveduras patogênicas pode levar ao desenvolvimento 
de fungemias. No presente estudo, avaliamos a prevalência de 
leveduras na cavidade bucal de pacientes HIV-positivos e verificamos 
se as espécies isoladas foram enzimaticamente ativas. Além disso, 
as espécies identificadas foram testadas quanto à suscetibilidade a 
antifúngicos. Métodos: Amostras de saliva e de candidose orofaríngea 
foram coletadas de 60 pacientes soropositivos para HIV e identificados 
pelo sistema API20C. A atividade enzimática foi avaliada pela 
produção de proteinase e fosfolipase. A suscetibilidade a antifúngicos 
foi determinada utilizando o método de microdiluição em caldo. 
Resultados: As espécies mais comumente isoladas foram C. albicans 
(51,56%), seguido por espécies de Candida não-albicans (43,73%), 
Trichosporon mucoides (3,12%) e Kodamaea ohmeri (1,56%). A 
colonização bucal por associação de diferentes espécies foi observada 
em 42% dos pacientes. A atividade enzimática foi verificada na maioria 
das espécies isoladas, com exceção de C. glabrata, C. lusitaniae e C. 
guilliermondii. Resistência ao fluconazol e anfotericina B foi observada 
em isolados de C. albicans, C. glabrata, C. parapsilosis, C. krusei, e 
K. ohmeri. Conclusão: Os pacientes HIV-positivos são colonizados 
por espécies únicas ou múltiplas de levedura que ocasionalmente são 
resistentes ao fluconazol ou anfotericina B.
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